NCT04394858

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2021-03-17Est. Completion: 2028-03-01

Enrollment target: 46 participants

Locations

Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Alaska Women's Cancer Care, Anchorage, Alaska, United States
Anchorage Oncology Centre, Anchorage, Alaska, United States
Katmai Oncology Group, Anchorage, Alaska, United States
Providence Alaska Medical Center, Anchorage, Alaska, United States
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
Holy Cross Hospital, Fort Lauderdale, Florida, United States
UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States
Saint Luke's Cancer Institute - Meridian, Meridian, Idaho, United States
Saint Luke's Cancer Institute - Nampa, Nampa, Idaho, United States

Malignant Neoplasm

Researchers are looking for new ways to treat adolescents with locally advanced, unresectable, or metastatic solid tumor…

Multiple LocationsEst. completion Jan 2, 2034

Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorHIF-2α Mutated Cancers

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocy…

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.